Should antiplatelet therapy be stopped prior to cataract surgery?

Antiplatelet Management for Cataract Surgery

Antiplatelets should NOT be stopped for cataract surgery. Continue aspirin and other antiplatelet agents through the perioperative period, as the risk of sight-threatening hemorrhagic complications is negligible while the cardiovascular risks of discontinuation are substantial.

Evidence-Based Rationale

Low-Risk Surgical Profile

• Cataract surgery with topical anesthesia and clear corneal incision is classified as a low bleeding risk procedure 1, 2, 3
• The most recent meta-analysis of 65,196 patients found that aspirin continuation increased only subconjunctival hemorrhage (RR: 1.74), which is a benign, self-limited complication with no visual consequences 1
• No increase in sight-threatening complications including hyphema, retrobulbar hemorrhage, vitreous hemorrhage, or posterior capsule rupture occurred with aspirin continuation 1

Safety of Continuation Across All Antiplatelet Agents

Aspirin monotherapy:

• Multiple studies confirm safe continuation with topical anesthesia 1, 3, 4, 5
• A large prospective cohort of 19,283 surgeries showed minimal absolute risk differences between continuation and discontinuation 5

Dual antiplatelet therapy (aspirin + clopidogrel):

• Even patients on combined aspirin and clopidogrel can safely undergo cataract surgery without stopping either agent 2
• A matched study of 38 patients on dual therapy showed no significant difference in hemorrhagic or non-hemorrhagic complications compared to controls 2
• No cases of anterior chamber hemorrhage, vitreous hemorrhage, or suprachoroidal hemorrhage occurred 2

Cardiovascular Risk of Discontinuation

• The thrombotic risk of stopping antiplatelets outweighs any minimal bleeding risk in cataract surgery 3, 4
• Rates of stroke, TIA, or deep vein thrombosis were 3.8/1000 surgeries among continuous users versus baseline rates, with discontinuation providing no clear benefit 5
• Myocardial infarction and ischemia rates were 5.1-7.6/1000 surgeries, with no improvement from discontinuation 5

Clinical Implementation

Anesthetic Technique Matters

• Use topical or intracameral anesthesia exclusively - avoid needle-based regional blocks (retrobulbar or peribulbar) 3, 4
• Clear corneal incision technique is essential for safety 2, 4
• These techniques minimize vascular trauma and bleeding risk even with antiplatelet continuation 3, 4

Guideline Context

While the 2022 CHEST guidelines address perioperative antiplatelet management broadly 6, they focus primarily on high-risk surgeries like CABG and major non-cardiac procedures. Cataract surgery falls into a distinctly different risk category and should not be managed according to guidelines designed for higher-risk interventions 1, 2, 3.

Common Pitfalls to Avoid

• Do not reflexively stop antiplatelets based on general perioperative guidelines - cataract surgery is a special case 3, 4
• Do not use needle-based anesthesia in anticoagulated/antiplatelet patients - this dramatically increases hemorrhage risk 3, 4
• Do not underestimate cardiovascular risk - elderly cataract patients often have significant cardiovascular disease requiring continuous antiplatelet protection 3, 5

Patient Counseling

• Inform patients they may experience increased subconjunctival hemorrhage (visible red eye), which resolves spontaneously without affecting vision 1
• Emphasize that continuing their cardiac medications is safer than stopping them 3, 5